CDEK
← All drugs Report issue

deucravacitinib

Trade name: Sotkyktu

Small moleculeapproved

Approved

Sep 9, 2022

Clinical trial activity

77 trials · 20 clinical orgs · 2 marketing orgs

Phase 1
28
Phase 2
37
Phase 3
21
Phase 4
10

Earliest trial started Apr 26, 2016 (NCT03419975)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2017

    Bristol-Myers Squibb — Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2017

    Bristol-Myers Squibb — Earliest Phase 2 Sponsor(trial)

2020s

  1. Sep 9, 2022

    Bristol-Myers Squibb — Earliest FDA Approval

  2. Sep 9, 2022

    Bristol-Myers — Marketing Organization

  3. Sep 9, 2022

    Bristol-Myers Squibb — NDA Secondary Org

  4. Sep 9, 2022

    Bristol-Myers Squibb — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedSep 9, 2022

Chemistry & pharmacology

Loading structure…

SMILES

[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC
Mol. weight
425.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

First in class

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07280702Phase 4Dec 15, 2025The University of Texas, Dallas
NCT07012057Phase 2Nov 21, 2025National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT06979453Phase 3Nov 15, 2025Bristol-Myers Squibb
NCT07116967Phase 3Sep 22, 2025Bristol-Myers Squibb
NCT06973291Phase 3Jul 9, 2025Takeda
NCT07013838Phase 4Jun 15, 2025Chinese Academy of Medical Sciences, Chinese SLE Treatment And Research Group
NCT07000630N/AJun 4, 2025Peking University
NCT06875960Phase 4Mar 17, 2025Bristol-Myers Squibb
NCT06869551Phase 3Mar 10, 2025Bristol-Myers Squibb
NCT06725264Phase 2Jan 31, 2025Bristol-Myers Squibb, Yale University
NCT06851871Phase 1Jan 23, 2025Bristol-Myers Squibb
NCT06532136Phase 2Nov 30, 2024Bristol-Myers Squibb, Icahn School of Medicine at Mount Sinai
NCT06566768Phase 1Oct 7, 2024Bristol-Myers Squibb
NCT06444399Phase 2Jul 29, 2024Mayo Clinic
NCT06476834Phase 4Jun 21, 2024Bristol-Myers Squibb
NCT06333860Phase 4May 10, 2024AbbVie
NCT06327321Phase 3May 5, 2024University of Nice Sophia Antipolis
NCT06281106Phase 2/Phase 3 (Phase 3)Apr 30, 2024University of Lausanne
NCT06220604Phase 3Mar 9, 2024—
NCT06143878Phase 3Feb 5, 2024—
Showing 20 of 77 trials
Page 1 / 4

Organizations

Research & Development (20)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit615542017
Harvard UniversityAcademic/Hospital2222023
Mayo ClinicAcademic/Hospital2212023
University of Nice Sophia AntipolisAcademic/Hospital2222024
AbbVieFor profit1112024
Chinese Academy of Medical SciencesAcademic/Hospital1012025
Chinese SLE Treatment And Research GroupAcademic/Hospital1112025
Dartmouth UniversityAcademic/Hospital1112023
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112024
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Government1112025
Peking UniversityAcademic/Hospital1112025
Taejoon Pharm Co., Ltd.For profit1112016
TakedaFor profit1112025
The University of Texas, DallasAcademic/Hospital1112025
University of Alabama, BirminghamAcademic/Hospital1112022
University of California, San FranciscoAcademic/Hospital1112023
University of LausanneAcademic/Hospital1112024
University of PennsylvaniaAcademic/Hospital1012023
Windsor DermatologyAcademic/Hospital1112022
Yale UniversityAcademic/Hospital1112025
20 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
Bristol-MyersFor profitMKTGSep 9, 2022
Bristol-Myers SquibbFor profitNDA2Sep 9, 2022
Bristol-Myers SquibbFor profitNDASep 9, 2022